StemCell Therapy

Xtalks Life Science Webinars

TORONTO (PRWEB) February 21, 2020

Pharmaceutical manufacturers are under increasing pressure to fast-track technological innovation to improve their manufacturing operations in order to adapt to new approaches like Industry 4.0 and continuous manufacturing, combat the growing and intense competition and keep up with the increasing demand for personalized medicine and therapies. But with an industry with the worlds tightest regulations and complex value chains, what are the correct steps to reaching operational intelligence in a GxP compliant manner with end-to-end data integrity?

Attend this webinar to learn:

Join speakers from Bigfinite including CEO Pep Gubau and Product Owner Christina Fernandez in a live webinar on Monday, March 9, 2020 at 1pm EDT to learn about how you can gain better knowledge of your operational realities and why you should consider GxP compliance today rather than delaying work to establish these regulatory systems now.

For more information or to register for this event, visit Why Companies Need GxP for their Digital Transformation Projects Now.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Read the rest here:
Why Companies Need GxP for their Digital Transformation Projects Now, Upcoming Webinar Hosted by Xtalks - PR Web

For women with advanced cases of cervical cancer, radiation therapy is generally the only curative treatment. The treatment of cervical cancer is unique, in that, brachytherapy, a form of radiation treatment where radioactive isotopes are placed within or near tumors, is a necessary component.

Dr. Michelle Ludwig, a radiation oncologist at the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, and Dr. Alexander Hanania, fourth-year resident physician in radiation oncology at Baylor, both see patients at Harris Health Systems Attwell Radiation Therapy Center at Smith Clinic. They are researching a way to make brachytherapy more efficient and less toxic for patients with cervical cancer.

Cervical cancer is a disease more common in medically underserved patients who have less access to screening and vaccination, Ludwig said. We are excited to work to bring access to personalized medicine in the form of a customizable device to the medically underserved patients in Harris County, as we have one of the highest volume centers in the country for this patient population.

Reserved solely for the most technical and challenging of cases, a procedure called interstitial brachytherapy allows doctors to deliver higher doses of radiation internally and directly to the tumor.

Interstitial brachytherapy is generally only needed for patients with large advanced tumors, or when there is another reason such as anatomical challenges or disease recurrence, Hanania said. In certain areas where we treat the uninsured population, more often than not, were seeing locally advanced disease, which often requires interstitial brachytherapy.

Historically, the procedure involves suturing a grid template to the body, then inserting a series of needles through the template holes and into the tissue involved with and surrounding the tumor. Radioactive isotopes are run through the needles to deliver the radiation and kill the tumor.

The procedure is highly effective in controlling and often curing cervical cancer that has not spread to other parts of the body, but it can also be damaging to the tissues and organs surrounding the cervix. According to Hanania, new devices on the market allow for more precise treatment but most are too expensive for most hospitals.

Last fall, Hanania visited Rice University with the hopes of finding an affordable solution. He presented the problem at an engineering design fair where students met with potential collaborators in a variety of industries. He met a group of five undergraduate students seniors Elisa Arango, Susannah Dittmar, Krithika Kumar and Sanika Rane and junior Lauren Payne all interested in addressing a global health issue.

We know that the women affected by cervical cancer have less access to healthcare, Dittmar said. These women shouldnt have to go through this painful, extensive treatment just because of their financial situation. We wanted to find a way to make the procedure better.

The group, which calls themselves Team At Your Cervix, got to work designing a new obturator that could be built with a 3D printer at Rices Oshmann Engineering Design Kitchen. After months of research and collaboration with Ludwig and Hanania, they now have a prototype called the Universally Friendly Obturator, or UFO.

Our goal was to reduce the number of transcutaneous needles, Dittmar said. The way were going to do that is by bringing them into the obturator so theyre going through the vaginal canal and not through the tissue.

The UFO is also wider than a traditional obturator and has a flexible head so the needles can better reach the cervix without disturbing the surrounding tissue.

Our goal was for it to be 3D printed so it can be an open sourced file, Payne said. Because were a global health project, it has to be low cost. The idea is that anyone in the world can access the file and print it.

In the coming months, the group will continue to develop and test new prototypes. They have designed simulations to see how the device would hold up in a real procedure

I think this device could decrease the morbidity of the implant. If its effective, it will not only shorten the amount of time that were in the operating room, it will also decrease the amount of trauma to the body, Hanania said. Every needle you put in increases the risk of trauma to other nearby parts of the body. This device would work with existing technology to make the therapy more targeted, and therefore less toxic.

The group will present their final prototype at the Rice Engineering Design Showcase at Tudor Fieldhouse on Thursday, April 16. After graduation, the team hopes another group of seniors will continue their work.

Dr. Hanania and Dr. Ludwig came to us with an actual problem that they face, said Rane, who will be attending Baylors School of Medicine in the fall. Our prototype can have an immense effect here in Houston and across the globe.

-By Molly Chiu

See the rest here:
Doctors team up with students to improve cervical cancer treatment - Baylor College of Medicine News

Are you in the United Kingdom and looking for a job in the life sciences? Or, are you planning on having a career in the life sciences? If so, then, youll be happy to know that there are an expected 133,000 jobs to be added to the sector over the next 10 years.

A new report called the Life Sciences 2030 Skills Strategy published in collaboration with theAssociation of the British Pharmaceutical Industry and the U.K.s Office for Life Sciences, forecasts the addition of 133,000 life science jobs by 2030. The jobs will range across the sector and include biopharma, medical devices and other areas of the industry. Specifically, the report predicts the addition of 43,000 jobs in biopharma, about 90,000 jobs in medtech and another 55,000 jobs to replace retirees across the sector.

The forecast does get a little more specific for the types of positions that will be needed in the U.K. over the next 10 years. For example, the report suggests that pharma research and development will require about 19,300 positions, while manufacturing roles in pharma will grow by about 6,400 jobs. While those are strong numbers, the report suggests that the medical device industry will see even greater growth.

The report projects 8,000 new jobs in medtech research and development and 46,500 jobs in medtech manufacturing.

For the other positions, the report suggests that by 2030, there will be an increase of 52,400 service and supply positions in the industry.

Alex Felthouse, managing director, Eisai Manufacturing and chairman of the Science Industries Partner Futures Group, a participant in the survey, said the strategy guide lays out the recommendations to take skills forward out to 2030 in support of the growing life sciences industry

To meet the demand that we have for the future we need to ensure that our industry is attractive to those who are considering joining the sector. We need to make them aware of all of the fantastic opportunities there are across a diverse and exciting range of activities from research and development through to medicines manufacturing. We also need toensure we have parity of esteem between different educational routes whether it be traditional academic routes, apprenticeships, vocational studies or ongoing continued professional development.

In order to capture some of these positions, the Life Sciences 2030 Skills Strategy outlines some of the key skills that will be needed by applicants. The skill sets include, as could be expected, proficiency in computers, as well as statistical literacy. The skills outlined are broad, but with the increasing reliance on machine learning and artificial intelligence in the pharmaceutical industry, that should provide more direction for potential applicants. The report notes that there is an accelerating convergence between life sciences, computer science, mathematics, statistics, engineering and chemistry in the fields of diagnostics, personalized medicine and data science.

There are also a number of soft skills that will be of benefit for future applicants. According to the survey, those kinds of skills will involve effective communication, leadership skills, sales and marketing abilities, as well as translational commercialization skills.

With the projected growth of jobs over the next 10 years, Nadhim Zahawim, business and industry minister for the U.K., said the government of the United Kingdoms hope is that the country will become a science superpower. By creating cutting-edge jobs in the life sciences industry, that will help the U.K. make progress in areas such as early medical diagnosis and manufacturing, Zahawim said in a statement. By providing a pathway for the growth, Zahawim said this will help level up every part of the UK with new opportunities.

In order to meet the demands, the government made several recommendations, including the implementation of an action plan from key stakeholders to oversee the growth of the industry. This action plan is aimed at encouraging and incentivizing the take-up of apprenticeships programs in all parts of the sector in order to establish parity of esteem with academic routes. Additionally, the action plan calls for supporting the transfer and exchange of a global workforce. The action plans have yet to be finalized, but when they are, the government said it will establish certain as-yet unnamed milestones and targets.

The government also points out that it will need to promote science, technology, engineering and mathematics programs to boost the increase of potential applicants, and also create a positive landscape that will attract and retain globally mobile talent. The strategy also notes that encouraging some academic researchers to shift into industry will also be key.

See original here:
Life Sciences Jobs Expected to Grow by 133,000 Over Next 10 Years in the UK - BioSpace

AI is rocking medical diagnosis with its potential to incite drastic improvements to hospital processes. AI can process images and patient health records with more accuracy and expediency than humans are capable of, lessening physician workload, reducing misdiagnosis, and empowering clinical staff to provide more value.

While early moving hospitals are already extracting value from AI in medical diagnosis, most US hospitals are at the very early stage of the AI transformation curve - and they risk falling behind if they don't move now.

In this report, Business Insider Intelligence examines the value of AI applications in three high-value areas of medical diagnosis - imaging, clinical decision support, and personalized medicine - to illustrate how the tech can drastically improve patient outcomes, lower costs, and increase productivity.

We look at US health systems that have effectively applied AI in these use cases to illustrate where and how providers should implement AI. Finally, we examine how a leading US health system validates AI partners and internally organizes its AI strategy to offer provider organizations a template for AI innovation.

The companies mentioned in this report are: Aidoc, Allscripts, Amazon, Arterys, Boston Gene, Cabell Huntington Hospital, Cerner, Cleveland Clinic, Epic, Geisinger Health System, Google, HCA Healthcare, IBM, iCAD, IDx, Intermountain Healthcare, Johns Hopkins, Meditech, Microsoft, Mount Sinai, NorthShore University HealthSystem, Oak Street Health, Stanford University, Tempus, UCI Health System, Unanimous AI, Verily, Viz.ai, and Yale New Haven Hospital.

Here are some of the key takeaways from the report:

In full, the report:

Want to learn more about the fast-moving world of digital health? Here's how to get access:

Read more:
AI IN MEDICAL DIAGNOSIS: How top US health systems are reacting to the disruptive force of AI by revolutionizi - Business Insider India

North American Prostate Cancer Diagnostics and Therapeutics Market Size, Share & Trends Analysis Report by Diagnostic Technique (Prostate-Specific Antigen Test, Digital Rectal Examination, Prostate Biopsy, Imaging Techniques) by Therapeutics (Hormonal Therapy, Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy, Surgery) and Forecast 2019-2025

North American prostate cancer diagnostics and therapeutics market is expected to grow at a CAGR of 10.4% during the forecast period. The major factors for the growth of the market include the high prevalence of prostate cancer in the region which raises the demand for efficient diagnostics and therapies for the treatment of cancer.

As per World Health Organization, in the North America, prostate cancer is the most prevalent cancer among men. Around 234,000 new cases of prostate cancer has been registered in 2018 in the region.

Additionally, in 2018, around 18.5% of the total cases of cancer are related to prostate cancer in the US. Moreover, the adoption of innovative technologies for the diagnosis of prostate cancer such as biomarkers and the adoption of personalized medicine for treatment is expected to fuel the market.

Report: http://www.omrglobal.com/requesttic-market

North American prostate cancer diagnostic market is divided on the basis of diagnostic technique and therapeutics. By diagnostic technique, the market is segmented into prostate-specific antigen test, digital rectal examination, prostate biopsy, imaging techniques.

Prostate biopsy is expected to hold a major market share during the forecast period. By therapeutics, the market is segmented into hormonal therapy, chemotherapy, immunotherapy, radiation therapy, targeted therapy, surgery.

During the forecast period, chemotherapy is expected to have a major market share in the region. Geographically, the market is divided into the US and Canada.

The US is expected to hold the major major market share during the forecast period.

Report: http://www.omrglobal.com/industrtic-market

North American Prostate Cancer Market Segmentation

By Diagnostic Techniques

By Therapeutics

Regional Analysis

Company Profiles

Report: http://www.omrglobal.com/report-tic-market

This email address is being protected from spambots. You need JavaScript enabled to view it.

Visit link:
North American Prostate Cancer Market scrutinized in the new analysis - WhaTech Technology and Markets News

Dublin, Feb. 12, 2020 (GLOBE NEWSWIRE) -- The "In-Vitro Toxicology/Toxicity Testing Market by Product & Services, Toxicity Endpoint & Test (Carcinogenicity, Dermal Toxicity), Technology (Cell-based, HTS), Method (Cellular Assays), Industry (Pharmaceutical, Cosmetics), Region-Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

The In-Vitro Toxicology Testing Market is Expected to Reach USD 12.7 Billion by 2024 from an Estimated USD 8.1 Billion in 2019, at a CAGR of 9.3%.

The opposition to animal testing, technological advancements, and increasing R&D expenditure to detect toxicity at an early stage during drug development are the primary growth factors for this industry.

The increasing focus of the pharmaceutical and cosmetics industries on using in-vitro methods for product testing along with the improvement in silico methods for predictive toxicology studies are expected to offer significant growth opportunities for players in this market. However, the dearth of skilled professionals is a substantial market challenge.

The software segment is expected to grow at the highest rate during the forecast period.

Based on the product & service, the in-vitro toxicology testing market is segmented into consumables, assays, equipment, software, and services. The software segment is projected to witness the highest growth in the in-vitro toxicology testing market during the forecast period.

Growth in this segment is driven mostly by the rising number of new technologies to develop in-vitro signatures and computational models capable of predicting in vivo responses. Also, the increasing use of the latest software in the industry and the academia to predict toxicity by comparing the data of new substances with other structurally or biologically similar compounds, are expected to drive the growth of this segment.

The ADME segment is expected to account for the largest market share in 2018.

Based on toxicity endpoints & tests undertaken across all industries, the in-vitro toxicity testing market is segmented into ADME; skin irritation, corrosion, and sensitization; genotoxicity; cytotoxicity; ocular toxicity; organ toxicity; phototoxicity; dermal toxicity; and other endpoints & tests. The ADME segment accounted for the largest share of the in-vitro toxicity testing market in 2018. This can be attributed to the high adoption during the drug development process with the advantage of producing highly reproducible & accurate data.

Toxicogenomics is expected to grow at the highest rate during the forecast period.

The toxicogenomics segment is expected to grow at the highest CAGR during the forecast period, primarily due to the technological advancements taking place in the field of proteomics and genomics. Also, the improvements in proteomic technologies are enhancing the study of gene & protein activity during toxicity analysis. Technological advancements taking place in the field of proteomics and genomics will further drive the growth of this segment in the coming years.

Europe is expected to hold the largest share for players operating in the in-vitro toxicology testing market.

Europe accounted for the largest share of the in-vitro toxicology testing market in 2018. Factors such as high adoption of in-vitro toxicology testing assays and services in the cosmetics and chemical industries after the ban on animal testing in the region are among the few factors expected to contribute to the growth of this market.

Story continues

Market Dynamics

Market Drivers

Opposition to Animal Testing

Technological Advancements

R&D Toward Early Stage Toxicity Detection

Market Restraints

Reluctance of Regulatory Authorities to Consider Alternative Methods for Proving Safety and Efficacy

Failure to Establish the Intricacies of in Vivo Conditions, In Vitro

Lack of In Vitro Models to Study Complex Endpoints

Market Opportunities

Market Challenges

Company Profiles

Bio-Rad Laboratories, Inc.

Bioivt

Catalent, Inc.

Charles River Laboratories International, Inc.

Covance, Inc.

Creative Bioarray

Creative Biolabs

Cyprotex PLC

Eurofins Scientific SE

GE Healthcare

Gentronix Limited

GVK Biosciences Private Limited

Insphero

MB Research Laboratories

Merck KGaA

Promega Corporation

Qiagen N.V.

SGS S.A.

Shanghai Medicilon Inc.

Thermo Fisher Scientific, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/gea7u2

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

More here:
In-Vitro Toxicology/Toxicity Testing Market Trends, 2019-2024 - Increasing Focus on Drug Discovery and Personalized Medicine Using In Vitro Methods -...

Global cell isolation market is expected to attain a CAGR of 18.8% during the forecast period.

The global cell isolation market accounted for $4.6 billion revenue in 2017, and it is expected to attain a CAGR of 18.8% during the forecast period (20182023). The demand for cell isolation products and services is increasing due to the rise in requirement for biopharmaceuticals, growing research activities in personalized medicine, and increasing government funding for research.

Cell isolation is the separation of one or multiple types of cells from a heterogenous cell population.

It has become an integral step in biological research, and routine diagnosis and treatment of certain diseases. Some cell types, such as blood cells, naturally exist in a separated form and thus can be isolated by employing centrifugation, whereas some others exist as solid tissues that require specific techniques to isolate the individual cell type.

The global cell isolation market is witnessing growth owing to the rising demand for biopharmaceutical products derived from natural sources, such as plants, animals, and humans, that are easier to manufacture than conventional pharmaceuticals.

Report at:www.psmarketresearch.com/market-ort-sample

The prevalence of neurological diseases, such as Parkinsons disease, amyotrophic lateral sclerosis, spinal cord injury, and autoimmune conditions, namely type 1 diabetes, multiple sclerosis, and Crohns disease is rising. This, coupled with the increasing awareness about these diseases, is impelling the governments of many countries to invest in biomedical research and related technology, thus giving a boost to growth of the cell isolation market and biopharmaceutical production as well.

People in developed countries are shifting toward personalized medicine, owing to their awareness and means to afford personalized treatment, as they can now avail of several reimbursement schemes. The advent of new technologies, such as genetic mapping via next-generation sequencing, which helps in identifying the gene responsible for a specific disease, is boosting the personalized medicine domain.

This growth in the personalized medicine domain is impacting the cell isolation market positively.

GLOBAL CELL ISOLATION MARKET SEGMENTATION

Market Segmentation by Product

Report: http://www.psmarketresearch.com/send-enion-market

Market Segmentation by Cell Type

Market Segmentation by Technique

Market Segmentation by Application

Market Segmentation by End User

This email address is being protected from spambots. You need JavaScript enabled to view it.

Continue reading here:
Growing Biomedical Research and Focus on Personalized Medicine to Aid Cell Isolation Market available in the latest report - WhaTech

A team of international clinicians and scientists on Wednesday published findings from a comprehensive review of more than 2,600 cancer genomes, which observers say could further pave the way for clinicians to prescribe precise treatments to cancer patients based on their genes.

The team, who published their findings in 23 papers in Nature and its affiliated journals, completed the research through a joint project of the International Cancer Genome Consortium (ICGC) and U.S.-funded Cancer Genome Atlas (TCGA) called the Pan-Cancer Analysis of Whole Genomes Project (PCAWG). The project involved more than 1,300 clinicians and scientists, including members of Harvard and the Broad Institute of MIT, from across 37 countries.

Whereas researchers in the past had only looked at 1% of the cancer genome that specifically codes for proteins, called the exome, this project analyzed the entire cancer genome. To understand this remaining 99%, a team of 16 working groups analyzed more than 2,600 whole genomes from 38 different tumor types using the field's largest publicly available whole-genome dataset. The project took six years.

The researchers were able to gain a more nuanced understanding of "driver mutations," or mutations that play a major role in driving cancer progression. While previous studies of the cancer exome had also shown common driver mutations, this study allowed the researchers to find more mutations in non-coding areas which have an impact on cancer progression. On average, the researchers found each type of cancer had four or five driver mutations. As a result of the research, only 5% of cancer tumors now have unknown genetic drivers.

These newly discovered driver mutations could potentially be new targets for new drugs and allow for more personalized care for cancer patients. Clinicians have long been frustrated that two patients with identical tumors can respond to the same treatments in different ways. This study moves the field closer to providing oncologists with a list of cancer-causing mutations that they can use to personalize treatment.

In addition, the researchers discovered a new way to "carbon date" cancer. The method allows researchers to identify old mutations involved in forming cancers and determine the relative timing between them. Using this technique, they found nearly 20% of mutations occurred years, or even decades, before the cancer was found. Fifty percent of these early mutations occurred in the same nine genes.

Gad Getz, a co-senior author of three of the papers and the director of bioinformatics at the Massachusetts General Hospital's Cancer Center and a professor of pathology at Harvard Medical School, said, "This large international effort shows the breadth of the types of research and new biological insight that are possible using whole cancer genome data."

Observers also noted that the findings could lead to better diagnostics and prevent cancer. "It's certainly true that this kind of sequencing will not mean that all cancers are cured," said Peter Campbell of the Wellcome Sander Institute, a PCAWG member. "But it points us to where we should be thinking about developing drugs for preventing resistance or treating it once it arises" (Drage O'Reilly, Axios, 2/6; McPherson, Harvard Gazette, 2/5; Kaiser, Science, 2/5).

Read the original:
A team of scientists examined more than 2600 cancer genomes. Here's what they found. - The Daily Briefing

New Jersey, United States, The report titled, Personalized Medicine Market Size and Forecast 2026 in Verified Market Research offers its latest report on the global Personalized Medicine market that includes comprehensive analysis on a range of subjects like competition, segmentation, regional expansion, and market dynamics. The report sheds light on future trends, key opportunities, top regions, leading segments, the competitive landscape, and several other aspects of the Personalized Medicine market. Get access to crucial market information. Market players can use the report back to peep into the longer term of the worldwide Personalized Medicine market and convey important changes to their operating style and marketing tactics to realize sustained growth.

Global Personalized Medicine Market was valued at USD 96.97 Billion in 2018 and is expected to witness a growth of 10.67% from 2019-2026 and reach USD 217.90 Billion by 2026.

Get | Download Sample Copy @https://www.verifiedmarketresearch.com/download-sample/?rid=7106&utm_source=ITN&utm_medium=002

Top 10 Companies in the Global Personalized Medicine Market Research Report:

Global Personalized Medicine Market: Competitive Landscape

Competitive landscape of a market explains strategies incorporated by key players of the market. Key developments and shift in management in the recent years by players has been explained through company profiling. This helps readers to understand the trends that will accelerate the growth of market. It also includes investment strategies, marketing strategies, and product development plans adopted by major players of the market. The market forecast will help readers make better investments.

Global Personalized Medicine Market: Drivers and Restrains

This section of the report discusses various drivers and restrains that have shaped the global market. The detailed study of numerous drivers of the market enable readers to get a clear perspective of the market, which includes market environment, government policies, product innovations, breakthroughs, and market risks.

The research report also points out the myriad opportunities, challenges, and market barriers present in the Global Personalized Medicine Market. The comprehensive nature of the information will help the reader determine and plan strategies to benefit from. Restrains, challenges, and market barriers also help the reader to understand how the company can prevent itself from facing downfall.

Global Personalized Medicine Market: Segment Analysis

This section of the report includes segmentation such as application, product type, and end user. These segmentations aid in determining parts of market that will progress more than others. The segmentation analysis provides information about the key elements that are thriving the specific segments better than others. It helps readers to understand strategies to make sound investments. The Global Personalized Medicine Market is segmented on the basis of product type, applications, and its end users.

Global Personalized Medicine Market: Regional Analysis

This part of the report includes detailed information of the market in different regions. Each region offers different scope to the market as each region has different government policy and other factors. The regions included in the report are North America, South America, Europe, Asia Pacific, and the Middle East. Information about different region helps the reader to understand global market better.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7106&utm_source=ITN&utm_medium=002

Table of Content

1 Introduction of Personalized Medicine Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Personalized Medicine Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Personalized Medicine Market, By Deployment Model

5.1 Overview

6 Personalized Medicine Market, By Solution

6.1 Overview

7 Personalized Medicine Market, By Vertical

7.1 Overview

8 Personalized Medicine Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Personalized Medicine Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Customization of Report Complete Report is Available @ https://www.verifiedmarketresearch.com/product/global-personalized-medicine-market-size-and-forecast-to-2026/?utm_source=ITN&utm_medium=002

Highlights of Report

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

TAGS: Personalized Medicine Market Size, Personalized Medicine Market Growth, Personalized Medicine Market Forecast, Personalized Medicine Market Analysis, Personalized Medicine Market Trends, Personalized Medicine Market

Read more:
Personalized Medicine Market 2020 Booming by Size, Revenue, Trend and Top Companies 2026 - Instant Tech News

Genedata and the Crohns & Colitis Foundation completed a project aimed at advancing precision care for Crohns disease patients.Genedata, a biopharmaceutical research and development software company, worked with foundation investigators and clinicians to integrate and study multi-omic and clinical data culled from patients with Crohns, which, along with ulcerative colitis, is among the most common forms of inflammatory bowel disease (IBD).The data will be used to identify the biomarkers that can be the most useful in evaluating, within five years of IBD diagnosis, a person's risk of developing disease complications that require surgery.Crohns disease is a chronic, often debilitating disease, for which there is currently no cure, Andres Hurtado-Lorenzo, PhD, the foundations senior director of translational research, said in a press release. Despite several treatment options, currently we lack predictive tests to determine the optimal treatment strategy early in the disease process, when the opportunity to improve outcomes is greatest.""There is a significant unmet need to advance new diagnostic tools to enable precision medicine approaches and to optimize patient care according to the severity of the disease course," he said.The foundation sought help with leveraging abundant clinical and molecular data. Multi-omics is an approach in which multiple datasets (such as genes or protein profiles) are combined and analyzed for new associations.Genedata used its precision medicine software platform, Genedata Profiler, to provide data analysis that could advance biomarker research efforts. Biomarkers are useful in predicting disease trajectory, which is crucial to personalized treatment plan development.We decided to im

Read the rest here:
Precision Medicine is Focus of Genedata, Crohn's Foundation Project - IBD News Today

First time findings published in Nucleic Acids Research demonstrate the ability to differentiate exosomes from cancer cell subtypes from the same tumor type offering broad potential applications in biomarker discovery

IRVING, Texas, Feb. 12, 2020 /PRNewswire/ -- Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the publication of new data in Nucleic Acids Research,illustrating that use of the Company's proprietary ADAPT Biotargeting System can lead to the identification of differences in protein expression patterns between exosomes from two related prostate cancer cell lines, vertebral cancer of the prostate (VCaP) and lymph node cancer of the prostate (LNCaP).

Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)

The paper, "ADAPT identifies an ESCRT complex composition that discriminates VCaP from LNCaP prostate cancer cell exosomes," also demonstrates that the ADAPT platform can be a powerful method that allows for the enrichment of polyligands that can distinguish even between different subpopulations of the same disease.

The results show that the ADAPT Biotargeting System has the resolution and sensitivity to discover differences in protein complexes using exosomes secreted by cancer cells from the same tumor type.

"The results of this research are highly significant in that they show that the ADAPT system can be deployed against multiple cancer types in various biological matrices and offers broad potential applications in biomarker discovery," said David Spetzler, M.S., Ph.D., M.B.A., President and Chief Scientific Officer of Caris Life Sciences, and an author of the study. "Further, we were able to show that in prostate cancer, ADAPT not only discriminated between cancer types but between subtypes of a specific lineage. We anticipate that this could potentially help inform treatment decisions based on the patient's specific molecular profile in prostate cancer and across a range of tumor types."

"The differences in the composition of the Endosomal Sorting Complex Required For Transport (ESCRT) pathway and associated complexes between exosomes derived from VCaP and LNCaP cells could point to them as novel biomarkers for these different prostate cancers," said Michael Famulok, Ph.D., University of Bonn (Germany), Life & Medical Sciences Institute (LIMES), Max Planck Fellow and co-author of the study. "We look forward to further investigating this potential and how the ADAPT system can be used to gain a greater understanding of the molecular composition of cells across tumor types."

The ADAPT Biotargeting System is Caris' proprietary unbiased profiling platform that uses a broad library of synthetically-manufactured molecules (aptamers) that bind to a wide range of biological targets and characterize complex biological systems in their native state, enabling them to profile biological samples at a systems-wide scale.

Thepaperwaspublishedonline on January 28 inNucleic Acids Research,andisavailableonlinehere and DOI:https://doi.org/10.1093/nar/gkaa034.

About Caris Life Sciences

Caris Life Sciences is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company's suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions.

Story continues

Caris is also advancing precision medicine with Next Generation Profiling that combines its innovative service offerings, Caris Molecular Intelligence and ADAPT Biotargeting System, with its proprietary artificial intelligence analytics engine, DEAN, to analyze the whole exome, whole transcriptome and complete cancer proteome. This information, coupled with mature clinical outcomes on thousands of patients, provides unmatched molecular solutions for patients, physicians, payers and biopharmaceutical organizations.

Whole transcriptome sequencing with MI Transcriptome provides the most comprehensive and unique RNA analysis available on the market and covers all 22,000 genes, with an average of 60 million reads per patient, to deliver extremely broad coverage and high resolution into the dynamic nature of the transcriptome. Assessing the whole transcriptome allows us to dig deeper into the RNA universe to uncover and detect fusions, splice variants, and expression changes that provide oncologists with more insight and actionable information when determining treatment plans for patients.

Caris Pharmatech, a pioneer of the original Just-In-Time research system with the largest research-ready oncology network is changing the paradigm from the traditional physician outreach model to a real-time approach where patient identification is completed at the lab and the physician is informed so that the patient can be enrolled days earlier, and remain in the local physician's care, without having to travel to a large central trial site. This fundamentally redefines how pharmaceutical and biotechnology companies identify and rapidly enroll patients in precision oncology trials by combining Caris' highest quality industry leading large-scale molecular profiling services with Pharmatech's on-demand site activation and patient enrollment system.

Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visitwww.CarisLifeSciences.comor follow us on Twitter (@CarisLS).

Media Contact:Lindsey BailysGCI Healthlindsey.bailys@gcihealth.com +1-212-798-9884

View original content to download multimedia:http://www.prnewswire.com/news-releases/study-shows-that-caris-life-sciences-adapt-biotargeting-system-has-discovered-protein-expression-pattern-differences-between-two-prostate-cancer-patient-subpopulations-301002804.html

SOURCE Caris Life Sciences

Read the rest here:
Study Shows That Caris Life Sciences' ADAPT Biotargeting System Has Discovered Protein Expression Pattern Differences Between Two Prostate Cancer...

Editors note:Brooks Bell is the founder and CEO of her eponymous brand consulting firm.

RALEIGH A year ago, I was diagnosed with stage 3 colon cancer. Its been a tough year: 6 months of surgery and chemotherapy, followed by intense health recovery. I have made dramatic changes to my diet, fitness routine, and stress. This month, I received the news Ive been fantasizing about all year: Im cancer-free. A groundbreaking blood test determined that there is not a single molecule of my tumor cells currently in my blood. That, combined with a clear CT scan, means that there is a 95% chance that my cancer is gone and wont return. I am overjoyed.

When I received the news, Jes and I were just waking up in the Dominican Republic after celebrating our 21st anniversary together. I burst into tears of joy, and felt the burden of uncertainty lifting off my chest. It was a surreal moment. Id gotten accustomed to clawing back my health, questioning feelings of wellbeing.It was easy to imagine being one of the unlucky ones who has the cancer come back and spread (after all, I was already unlucky enough to get cancer in the first place).

This is what makes cancer so hard for many: even when youre done with your treatment, it takes years to fully relax again because up until now our existing technology has prevented us from knowing if the treatment was truly successful.

Not anymore.

The molecular test that I took is a cutting-edge technology calledNatera. It gives cancer patients personalized testing that involves doing ultra-deep DNA sequencing on your tumor cells, and then matching those to your blood to see if they are still floating around in your body.

It just got FDA breakthrough status in May, and I was the first patient at Duke Cancer Center to receive it.

I believe this test may be part of a paradigm shift in the cancer industry. Its a perfect example of the promise of personalized medicine and machine learning. It is going to give patients clear insight on whether their treatment has been successful, and maybe even if chemotherapy is even necessary for them. Its pretty incredible, and I am so lucky to be able to benefit from it. Go Duke! Go Natera!

Brooks Bells new cause. (Brooks Bell image)

I will be celebrating toasting my health and the50 Colonoscopies Under 50 honorees with my friends and supporters at The Colonoscopy Gala on Feb. 28 at CAM Raleigh. I would love for you to be there with me (especially if you are based in NC).

This may be the first ever Colonoscopy Gala in the history of time. A colonoscopy is the most effective way to protect yourself from colon cancer, and it deserves a night to be celebrated.

Itll be an evening to remember. We will have asuper talented chefdoing a five-course seated dinner for us, and you may be able to even get bring home a one-of-a-kind street-artist designedTushy Ottoman..

And of course, its for a good cause; all proceeds go to the astonishingly underfunded Colorectal Cancer Alliance.

Tickets are $175 each, and are available until Feb. 17. RSVP or donate here.

Brooks Bell: I finished my chemo treatment, feeling fantastic

Six months after cancer diagnosis, Brooks Bell appoints successor to run her brand consulting firm

Go here to see the original:
Brooks Bell: 'Groundbreaking blood test determined there is 95% chance my cancer is gone and won't return' - WRAL Tech Wire

Parsippany, NJ, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq:IDXG) today announced that the Center for Medicare and Medicaid Services (CMS) has modified the reimbursement for Interpace Diagnostics ThyraMIR miRNA classifier for evaluating indeterminate thyroid nodules retroactively to January 1, 2020. This determination increases the Medicare reimbursement for ThyraMIR from approximately $1800 to $3000 reflecting a re-evaluation of the technical and clinical performance of the test relative to other molecular tests in the market and their respective prices. Today, approximately 30% of the Companys ThyraMIR volume is attributable to Medicare eligible patients.

According to Jack Stover, CEO of Interpace, We are pleased with the thorough assessment given by CMS in evaluating one of our key products with the result of improved pricing for ThyraMIR. We believe this modification represents value-based pricing and reflects the critical impact ThyraMIR has on identifying a surgical need from surveillance. This price improvement is particularly noteworthy in light of our recent announcement surrounding the preliminary approval from CMS for a price increase in Interpaces biomarker companion product ThyGeNEXT.

About ThyGeNEXT and ThyraMIR

ThyGeNEXT utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma. ThyraMIR is the first microRNA gene expression classifier. MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of genes involved in human cancers, including every subtype of thyroid cancer. ThyraMIR measures the expression of 10 microRNAs. Both ThyGeNEXT and ThyraMIR are covered by Medicare and Commercial insurers, with more than 280 million members covered.

According to the American Thyroid Association, approximately 20% of the 525,000 thyroid fine needle aspirations (FNAs) performed on an annual basis in the U.S. are indeterminate for malignancy based on standard cytological evaluation, and thus are candidates for ThyGeNEXT and ThyraMIR.

ThyGeNEXT and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules. The combination of both tests can improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis.

About Interpace Biosciences

Interpace Biosciences is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Interpace Diagnostics is a fully integrated commercial and bioinformatics business unit of Interpace Biosciences that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX that differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Interpace Pharma Solutions Is a business unit of Interpace Biosciences that provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. The Pharma Solutions Business also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

Story continues

For more information, please visit Interpace Biosciences website at http://www.interpace.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

CONTACTS:Investor Relations - Edison GroupJoseph Green(646) 653-7030jgreen@edisongroup.com

See the original post here:
Interpace Biosciences Announces Another Pricing improvement for its Thyroid Assay - Yahoo Finance

Dataintelo.com, has added the latest research on Personalized Medicines Market, which offers a concise outline of the market valuation, industry size, SWOT analysis, revenue approximation, and the regional outlook of this business vertical. The report precisely features the key opportunities and challenges faced by contenders of this industry and presents the existing competitive setting and corporate strategies enforced by the Personalized Medicines Market players.

As per the Personalized Medicines Market report, this industry is predicted to grow substantial returns by the end of the forecast duration, recording a profitable yearly growth in the upcoming years. Shedding light on brief of this industry, the report offers considerable details concerning complete valuation of the market as well as detailed analysis of the Personalized Medicines Market along with existing growth opportunities in the business vertical.

Request a sample Report of Personalized Medicines Market at: https://dataintelo.com/request-sample/?reportId=98645

Concepts and ideas in the report:Analysis of the region- based segment in the Personalized Medicines Market: As per the report, in terms of provincial scope, the Personalized Medicines Market is divided into USA, Europe, Japan, China, India and South East Asia. It also includes particulars related to the products usage throughout the geographical landscape. Data related to the evaluations held by all the zones mentioned as well as the market share registered by each region is included in the report. Sum of all the product consumption growth rate across the applicable regions as well as consumption market share is described in the report. The report speaks about consumption rate of all regions, based on product types and applications.

Brief of the market segmentation: As per the product type, the Personalized Medicines Market is categorized intoPM DiagnosticsPM TherapeuticsPersonalized Medical CarePersonalized Nutrition & Wellness

Furthermore, the market share of each product along with the project valuation is mentioned in the report. The report consists of facts related to every single products sale price, revenue, growth rate over the estimation time period.

The Personalized Medicines Market, according to the application spectrum, is categorized intoHospitals PharmaciesRetail PharmaciesDietary Care CentersOthers

Data pertaining the market share of each product application as well as estimated revenue that each application registers for is slated in the report.

Propelling factors & challenges: The report provides data concerning the forces influencing the commercialization scale of the Personalized Medicines Market and their effect on the revenue graph of this business vertical. Data pertaining to latest trends driving the Personalized Medicines Market along with the challenges this industry is about to experience in the upcoming years is mentioned in the report.

Ask for Discount on Personalized Medicines Market Report at: https://dataintelo.com/ask-for-discount/?reportId=98645

Implementing marketing tactics: Ideas about numerous marketing strategies implemented by the renowned shareholders with respect to product marketing is present in the report. Information related to the sales channels that companies select is also included in the report. Along with the dealers of these products, it also presents the summary of the top customers for the same.

Analysis of the major competitors in the market:An outline of the manufacturers active in the Personalized Medicines Market, consisting of3G BiotechQuest DiagnosticsLaboratory Corporation of AmericaAbbottAgendia NVAsuragen IncBecton DickinsonCardioDx Inc.Foundation MedicineQiagenSiemens HealthcareAmgenBristol-Myers SquibbGE HealthcarePfizerSanofi23andMeIlluminaalong with the distribution limits and sales area is reported. Particulars of each competitor including company profile, overview, as well as their range of products is inculcated in the report. The report also gives importance to product sales, price models, gross margins, and revenue generations. The Personalized Medicines Market report consists of details such as estimation of the geographical landscape, study related to the market concentration rate as well as concentration ratio over the estimated time period.

To Buy this report, Visit : https://dataintelo.com/checkout/?reportId=98645

Some of the Major Highlights of TOC covers:Personalized Medicines Regional Market Analysis Personalized Medicines Production by Regions Global Personalized Medicines Production by Regions Global Personalized Medicines Revenue by Regions Personalized Medicines Consumption by Regions

Personalized Medicines Segment Market Analysis (by Type) Global Personalized Medicines Production by Type Global Personalized Medicines Revenue by Type Personalized Medicines Price by Type

Personalized Medicines Segment Market Analysis (by Application) Global Personalized Medicines Consumption by Application Global Personalized Medicines Consumption Market Share by Application (2014-2019)

Personalized Medicines Major Manufacturers Analysis Personalized Medicines Production Sites and Area Served Product Introduction, Application and Specification Personalized Medicines Production, Revenue, Ex-factory Price and Gross Margin (2014-2019) Main Business and Markets Served

For More Information on this report, Request Inquiry At https://dataintelo.com/enquiry-before-buying/?reportId=98645

About DataIntelo: DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info DataIntelo Name Alex Mathews Email [emailprotected] Website https://dataintelo.com Address 500 East E Street, Ontario, CA 91764, United States.

Read more:
Personalized Medicines Market, Share, Growth, Trends And Forecast To 2025 DataIntelo - Keep Reading

lacaosa via Getty Images

Prolon provides dieters with bars, soups, drinks, and supplements said to deliver the benefits of intermittent fasting byusing ingredients that "are not recognized as food by your body," according to its website.

Intermittent fasting of any kind has promising health benefits, including potentially slowing aging and diseases like cancer and diabetes.

But more research is needed before experts can be sure it's beneficial, or even not harmful, long term. Plus, it's unsafe for certain populations, like people at risk for eating disorders.

Dr. Caroline Apovian, professor of medicine in endocrinology, diabetes, nutrition and weight management at Boston University School of Medicine, previously told Insider that the only studies done on fasting diets have been small.

"We are getting insight into early time restricted eating but there is no solid research there yet it may be that a period of fasting during night hours is good for your metabolism but studies are still coming," Apovian said.

Read this article:
Oscars 2020: The science behind the wellness swag in nominee gift bags - Insider - INSIDER

Global Precision Medicine Market By Application (Diagnostics, Therapeutics and Others), Technologies (Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics and Others), Indication (Oncology, Central Nervous System (CNS) Disorders, Immunology Disorders, Respiratory Disorders, Others), Drugs (Alectinib, Osimertinib, Mepolizumab,Aripiprazole lauroxil and Others), Route of Administration (Oral,Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Precision Medicine Marketto grow with a substantial CAGR in the forecast period of 2019-2026. Growing prevalence of cancer worldwide and accelerating demand of novel therapies to prevent of cancer related disorders are the key factors for lucrative growth of market

Download Free PDF Sample Copy of Report@http://databridgemarketresearch.com/request-a-sample/?dbmr=global-precision-medicine-market

Key Market Players:

Few of the major competitors currently working in the global precision medicine market are Neon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG, PERSONALIS INC, GENOCEA BIOSCIENCES, INC., F. Hoffmann-La Roche Ltd, CureVac AG, CELLDEX THERAPEUTICS, BIONTECH SE, Advaxis, Inc, GlaxoSmithKline plc, Bioven International Sdn Bhd, Agenus Inc., Immatics Biotechnologies GmbH, Immunovative Therapies, Bristol-Myers Squibb Company, Gritstone Oncology, NantKwest, Inc among others.

Competitive Analysis:

Theprecision medicine marketis highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of mass spectrometry market for global, Europe, North America, Asia Pacific and South America.

Market Definition:

Precision medicines is also known as personalized medicines is an innovative approach to the patient care for disease treatment, diagnosis and prevention base on the persons individual genes. It allows doctors or physicians to select treatment option based on the patients genetic understanding of their disease.

According to the data published in PerMedCoalition, it was estimated that the USFDA has approved 25 novels personalized medicines in the year of 2018. These growing approvals annually by the regulatory authorities and rise in oncology and CNS disorders worldwide are the key factors for market growth.

Talk to The Author of Report @http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-precision-medicine-market

Market Drivers

Market Restraints

Key Developments in the Market:

Competitive Analysis:

Global precision medicine market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global precision medicine market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

SHORT Table of Contents

1.1. OVERVIEW OF THE GLOBAL PRECISION MEDICINE MARKET

1.2. CURRENCY AND PRICING

1.3. LIMITATION

1.4. MARKETS COVERED

2 MARKET SEGMENTATION

2.1. KEY TAKEAWAYS

2.2. ARRIVING AT THE GLOBAL PRECISION MEDICINE MARKET SIZE

2.3. GLOBAL PRECISION MEDICINE MARKET: RESEARCH SNAPSHOT

2.4. ASSUMPTIONS

3 MARKET OVERVIEW

3.1. DRIVERS

3.2. RESTRAINTS

3.3. OPPORTUNITIES

3.4. CHALLENGES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 GLOBAL PRECISION MEDICINE MARKET, BY TECHNOLOGY

6.1. OVERVIEW

6.2. BIG DATA ANALYTICS

6.3. BIOINFORMATICS

6.4. GENE SEQUENCING

6.5. DRUG DISCOVERY

6.6. COMPANION DIAGNOSTICS

6.7. OTHERS

7 GLOBAL PRECISION MEDICINE MARKET, BY APPLICATION

7.1. OVERVIEW

7.2. ONCOLGY

7.3. HEMATOLOGY

7.4. INFECTIOUS DISEASES

7.5. CARDIOLOGY

8 GLOBAL PRECISION MEDICINE MARKET, BY end-user

8.1. OVERVIEW

8.2. PHARMACEUTICALS

8.3. BIOTECHNOLOGY

9 GLOBAL PRECISION MEDICINE MARKET: COMPETITIVE LANDSCAPE

9.1. GLOBAL PRECISION MEDICINE MARKET: COMPANY SHARE ANALYSIS

9.2. MERGERS & ACQUISITIONS

9.3. NEW PRODUCT DEVELOPMENT & APPROVALS

9.4. EXPANSIONS

10 GLOBAL PRECISION MEDICINE MARKET, COMPANY PROFILES

10.1 Orion Health

10.2 ARIEL Precision Medicine, INC.

10.3 Metabolon, Inc.

10.4 Pfizer Inc.

10.5 Biocrates Life Sciences

10.6 Medtronic

10.7 NovartisAG

10.8 Quest Diagnostics Incorporated

10.9 F. Hoffmann-La Roche Ltd

10.10 Teva Pharmaceutical Industries Ltd

11 APPENDIX

12 ABOUT DATA BRIDGE MARKET RESEARCH

Get a Detail TOC @http://databridgemarketresearch.com/toc/?dbmr=global-precision-medicine-market

Market Segmentation:

By technology:-big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics, and others.

By application:- oncology, hematology, infectious diseases, cardiology, neurology, endocrinology, pulmonary diseases, ophthalmology, metabolic diseases, pharmagenomics, and others.

On the basis of end-users:- pharmaceuticals, biotechnology, diagnostic companies, laboratories, and healthcare it specialist.

On the basis of geography:- North America & South America, Europe, Asia-Pacific, and Middle East & Africa. U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others.

In 2017, North America is expected to dominate the market.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:Corporatesales@databridgemarketresearch.com

Go here to read the rest:
Global Precision Medicine Market Analysis And Growth Forecast By Applications, Sales, Size, Types And Competitors By 2020-2026 - Reporting 99

Future Free Trade Agreementsand NHS

Trump has been openly expressing his interest to strike a free trade deal with the UK. The US president has also blamed the freeloading countries benefiting from US pharmaceutical research and extorting unreasonably low prices from US pharma reiterating that the US has great power over the trading partners. While the president denied the UKs NHS being on a trade talk table during the 70th anniversary of NATO, speculations about Trumps interest in the NHS do exist.

The major concern is that the US will want its pharma companies to gain greater commercial access to the NHS as part of a trade deal, which could force UK healthcare services into paying higher prices for US drugs.

The year 2020 will see continued pressure on the UKs medicines supply chain. While the biggest feardrug shortage associated with No Deal Brexit is out of the picture, at least during the transition period, the concerns surrounding the drug supply chain still exists.

If the UK leaves the European Medicines Agencys (EMAs) drug approval system and develops its own, Britain is at risk of getting delayed access to new medicines.

The announcement of the Medicines and Medical Devices Bill, which includes relaxing some regulations around clinical trials, speeding up the approval of innovative medicines, facilitating the prescription process of low-risk medicines and extending the UKs lead in personalized medicine and artificial intelligence, looks promising. Nevertheless, there is not much progress and clarity on what actions will be taken to bring these initiatives forward.

Another risk can derive from the failure to implement EU Clinical Trials Regulation within the UKs regulatory system, which could affect UK participation in multinational clinical trials.

Read more from the original source:
Brexit: It Will Take Years for the UK Healthcare Sector to Stabilize - MedicalExpo e-Magazine

NIH research is working hard to solve the puzzle of how genes and lifestyle connect to affect our lives and our health. Today, researchers can scan and compare entire genomes very quickly. These studies have already turned up disease signatures for type 2 diabetes, heart disorders, prostate cancer, Crohns disease, Parkinsons disease, and age-related macular degeneration. More disease-related gene variants are identified every few months.

The Human Genome Project and thousands of follow-on studies are helping scientists to develop gene-targeted treatments. A poignant example is the case of a woman with lung cancer that had spread to her brain. Diagnosed in 2002, this 44-year-olda vegetarian who had never smokedunderwent various therapies to stave off what seemed inevitable. Then came a miracle: she learned of a clinical trial testing a new drug, getfitinib, that for some tumors appeared to work as a genetic smart weapon. Her tumor was one of those, and she is alive today because of medical research.

Thanks to NIH-funded basic research that gave us genetic engineering and launched the $40 billion biotech industry, DNA is a household name. Virtually every biomedical research lab and pharmaceutical company throughout the world uses the power of the genomic revolution every day to demystify diseases and find new cures. Within 5 years, the complete DNA instruction bookor whole genomeof an individual will read out for less than $1,000, making genetic analysis a routine part of medical care.

One recent study provides a glimpse of how whole-genome sequencing might eventually be used in the clinic. Scientists evaluated the entire genome of a 40-year-old man to determine his risk for dozens of diseases and his likely response to common drugs. They pinpointed gene variants linked to several diseases in the mans family, including vascular disease and early sudden death. They also found variants linked to conditions not known to be in his family, such as thyroid and parathyroid diseases. Other gene variants predicted the patients likely responses to certain heart medicationsinformation thats especially relevant since hes at risk for cardiovascular disorders.

Remarkable advances in the field of pharmacogenomicshow individuals react differently to medicinesindicate that we are moving away from one-size-fits-all medicine. Scientists can now identify glitches in our DNA scripts that reveal what drugs may be dangerousor completely ineffectivefor certain people. This information will help doctors calculate precise dosages that match a persons DNA.

Collectively, research results in this important area of biomedicine are prompting the U.S. Food and Drug Administration (FDA) to consider changing the labeling requirements for important medicines taken by millions of Americans. Already, pharmacogenomic information is contained in about 10% of labels for drugs approved by the FDA to treat a range of conditions including HIV/AIDS, cancer, seizures, and cardiovascular disorders.

Next: Stem Cells

Read more here:
Personalized Medicine | National Institutes of Health (NIH)

Say precision medicine and people think of personalized cancer treatment. But this innovation has already begun to revolutionize primary care tooeven though the jury is still out, in many cases, on whether it makes a clear difference in outcomes.

Just what precision (alias personalized) medicine is isnt always spelled out precisely. But usually it is discussed as prevention or treatment that takes into account individual differences among patients, most often genetic differences. Some people expand the concept to consider individual differences in environment and lifestyle.

In adult primary care, two subsets of precision medicine have attracted the most attention recently: predictive genetic testing and pharmacogenomics.

Predictive genetic testing is what it sounds like: A genetic test that forecasts a persons chance of getting a disease. The term is also applied to germline genetic tests that provide some indication of the predisposition being passed down to offspring. Proponents see predictive genetic testing for certain inherited conditions as a way to unearth risks in people who can then get early treatment or take preventive steps to head off serious and possibly costly conditions. Actor Angelina Jolie put BRCA testing as a predictive genetic test into the public consciousness with her announcement in 2013 that she underwent a double mastectomy after testing positive for a BRCA mutation.

Pharmacogenomics studies show how a persons genes can affect his or her response to medications. Ideally, pharmacogenomic (sometimes called pharmacogenetic) results could end some of the trial and error with drugs and help providers and patients choose the most effective drug right off the bat.

Where federal dollars are concerned, precision medicine has already stepped out of the cancer box. In 2015, President Barack Obama committed $215 million to precision medicine research, including a genomic study of more than a million Americans to extend precision medicine from cancer to other diseases. A year later, the 21st Century Cures Act expanded this funding to $1.5 billion over the next 10 years.

Aided by a multibillion-dollar genomic testing industry, some providers have started testing precision medicine beyond oncology. In 2018, Geisinger Health System in central Pennsylvania made a splash by announcing that it would add DNA sequencing to routine primary care. A small number of other hospitals are starting to monetize these tests. In August 2019, STAT reported that a handful of academic medical centers, including Brigham and Womens Hospital and the Mayo Clinic, have started elective genome sequencing clinics for generally healthy patients willing to pay hundreds, sometimes thousands of dollars in cash for a genetic workup.

Skeptics see carts preceding horses; solid evidence that routine genetic testing results in better outcomes is lacking. As one genome-sequencing clinic leader conceded in the STAT article, such testing can lead to expensive follow-up testing. Not surprisingly, payers have been reluctant to cover sequencing tests of various kinds.

Regulators have breathed life into some kinds of testing and poured cold water on others. Last year, 23andMe was the first testing company to get FDA approval to market a direct-to-consumer genetic test for three (of the more than 1,000 known) BRCA gene mutations linked to increased risk of breast, ovarian, and prostate cancer. But in April 2019, the agency issued a warning letter to Inova Health System in Northern Virginia to stop marketing pharmacogenomics tests it claimed could predict patients responses to antidepressants, opioids, and other drugs. The FDA said it was unaware of data to support these claims.

A survey published two years ago in Clinical Pharmacology and Therapeutics found that clopidogrel, a blood thinner, was the medication most commonly tested for a druggene interaction, followed by simvastatin and warfarin. Nearly 40 academic medical centers and community health systems testing ways to implement pharmacogenomics in clinical practice were surveyed.

Some evidence suggests that traditional screening methods may not identify everyone at risk for certain inherited conditions. In a study published in Science three years ago, researchers at Geisinger and Regeneron (which manufactures Praluent, a drug used to treat familial hypercholesterolemia) found that only about one in four people carrying the familial hypercholesterolemia gene variant met the Dutch Lipid Clinic Network criteria (widely used diagnostic criteria) for genetic testing. Still, evidence for the clinical utility of many pharmacogenomic or predictive genetic tests is pretty scanty at this point.

Right now, for the average primary care provider, there are a relatively limited number of situations where pharmacogenomic testing is clearly beneficial to outcomes in a way thats dramatic, says Greg Feero, MD, a faculty member at Maine Dartmouth Family Medicine Residency and a former senior advisor to the director of the NIHs genomics research division.

For predictive genetic testing, there are a few notable exceptionshereditary breast and ovarian cancer, Lynch syndrome, and familial hypercholesterolemiaif certain criteria such as family history of the condition are met. The CDC has designated genomics applications for these conditions as Tier 1, the highest tier on its evidence-based ranking system of genomic applications by their potential for a positive public health impact.

In a 2017 editorial published in American Family Physician, Vinay Prasad, MD, and Adam Obley, MD, of Oregon Health and Science University said that rigorous meta-analyses havent yet shown that genotype-guided dosing for warfarin, clopidogrel, or antidepressant selection is better than usual care. Prasad is a well-known critic of what he sees as the proliferation of medical treatments and therapies without good evidence behind them. We need to know on a broad scale that [these tests] improve outcomes for patients, and dont just reassure physicians theyre choosing a better drug, Obley tells Managed Care.

Prasad and Obley also argued in their editorial that without further proof of improved outcomes, routine genetic testing could just fuel more inappropriate care. Guidelines carve out clear boundaries for who should get tested because there are scenarios in which the risks and benefits of preventive measures arent known, they said, noting that the U.S. Preventive Services Task Force advises against genetic testing for BRCA mutations in women without a family history of BRCA-related cancers.

A small pilot study suggests that genetic testing in primary care may not lead to improved outcomes. In 2017, The Annals of Internal Medicine published the first randomized trial of whole-genome sequencing in primary care. Gene variants were found in 20% of the participants whose genomes were sequenced. But six months later none of them had improved outcomes.

The test produces lots of information, says Obley, who wasnt involved in the study. But its not clear that any patient was managed differently in a way that improved their health.

Without evidence supporting the clinical utility of routine pharmacogenomics or genetic testing, most payers are unwilling to cover them. Some exceptions exist, such as employers that offer routine genetic testing as an employee benefit. In a blog post published in 2018, Color Genomics touted Visa and the German software company SAP as customers. Medicare covers pharmacogenomic testing of two gene variants that predict warfarin responsiveness for beneficiaries enrolled in a randomized, controlled clinical study that meets certain standards.

The high cost of genetic testing has been cited as another reason insurance coverage is limited, but payers may not budge even as testing gets cheaper. The cost of doing the test itself has been declining quite rapidly, says Kathryn Phillips, a health economics professor at University of CaliforniaSan Francisco who researches personalized medicine access, quality, and reimbursement. She has disclosed in recent studies that she is a paid consultant for Illumina, a DNA sequencing company. But she says its hardand its going to take longerto figure out where to use genetics in primary care in healthy populations, and [for insurers] to pay for it.

The current state of evidence and bleak reimbursement prospects havent deterred early adopters from embracing precision medicine in primary care. For Megan Mahoney, MD, chief of general primary care at Stanford Medicine, precision medicine begins with going after data on key determinants of healthnot just genes, but also environmental factors, social determinants, and health behaviors.

In a yearlong pilot of 50 patientsmore than half of whom were at risk for cardiovascular conditionsStanford Medicine care teams created personalized care plans to prevent and manage chronic illness. The plans leveraged data from several sources, including genetic-risk assessments and genetic testing for the three CDC Tier 1 conditions and remote monitoring devices.

Before the pilot, which ended in 2018, Stanford did not offer routine genetic testing in primary care. So far, that hasnt changed. But Stanford is making the genetic-risk assessment tested in the pilot available to its primary care providers, hoping it can increase screening rates for the Tier 1 conditions, says Mahoney. Studies show that many primary care providers are uncomfortable evaluating and addressing genetic risk. Five patients in the pilot discovered through the genetic risk screening that theyre at high risk for breast cancer, demonstrating that this type of tool can help to identify previously unknown risks.

Post-pilot, Stanford is also offering patients with poorly controlled blood pressure connection to a Bluetooth-enabled blood pressure cuff and health coaching as part of a larger study. Genetic testing has dominated the discussion of precision medicine in primary care, but Stanfords experience shows that it isnt the only way to tailor preventive care to individual patients needs.

Even if clinical utility is ultimately shown, folding precision medicine into primary care will likely follow the path of many new developments in medicine: There will be some early adopters, but most practices will have a wait-and-see and depends-on-the-reimbursement attitude.

Educating doctors on how to interpret, use, and communicate genetic testing results to patients will be one of the biggest hurdles. Theyll be learning on the job, says Susanne Haga, associate professor of internal medicine at Duke Universitys medical school, who leads educational activities in genetics and genomics for the Duke Center for Applied Genomics. An obstacle course of other possible barriers awaits: the limited number of certified genetic counselors, concerns about privacy and genetic discrimination, and the potential for the lack of diversity in genomic data sets to exacerbate disparities in care.

Still, Haga sees the convergence of three factors that will force the health care systems hand and usher in precision medicine in primary care: patients increasing ability to influence decisions about their care, the declining cost of testing, and a critical mass of people, numbering in the millions, who will have had their DNA sequenced in genome programs such as Geisingers or several national genomics research initiatives.

Its coming, she says, one way or another.

Read more:
Precision Medicine in Primary Care: Bespoke. Genetic and Genomic. And Maybe Not Ready. - Managed Care magazine

Precision medicine promises a new paradigm in oncology where every patient receives truly personalized treatment. This approach to disease diagnosis, treatment and prevention utilizes a holistic view of the patientfrom their genes and their environment to their lifestyleto make more accurate decisions.

Growing at a rate of 10.7 percent, the precision medicine market is expected to exceed $96 billion by 2024.1 Bioinformatics represent a significant share of the market, as bioinformatics tools enable the data mining necessary for rapid identification of new drug targets and repurposing of existing treatments for new indications.1 (Reuters) The oncology segment of the precision market is expected to experience an 11.1 percent compounded annual growth rate (CAGR) leading up to 2024 due to the success of recent targeted therapies and subsequent high demand.

Still, precision medicine is in its infancy, and making personalized treatment a reality for all patients requires a transformation in how novel therapies are developed and delivered. New regulatory, technical, clinical and economic frameworks are needed to ensure that the right patients are able to access the right therapy at the right time. In this article, we review the current state of precision medicine in oncology and explore some of the challenges that must be addressed for precision medicine to reach its full potential.

Great strides toward precision medicine are being made in the area of cancer immunotherapy, which is designed to boost a patients own immunity to combat tumor cells. The introduction of immune checkpoint inhibitors (PD-1/PD-L1 and CTLA-4 inhibitors) revolutionized treatment for certain hematologic malignancies and solid tumors. To date, immune checkpoint inhibitors have been approved by the U.S. Food and Drug Administration (FDA) for more than 15 cancer indications, but their widespread use has been hampered by unpredictable response rates and immune-related adverse events.

The approvals of the first chimeric antigen receptor (CAR)-T cell (CAR-T) therapies in 2017 were the next leap forward in precision medicine. These immunotherapies demonstrated that it was possible to take out a patients own T-cells, genetically modify them, and then put them back in to target cancer cells. With complete remission rates as high as 83 percent within three months of treatment, CAR-T therapies represent a seismic shift in our approach to cancer, bringing the elusive possibility of a cure one step closer. However, longer-term follow-up has shown that these remissions may not be durable2 and prevention of relapse must still be studied.

Ultimately, the goal of cancer immunotherapy is to stimulate the suppressed immune system of a patient with cancer so that it can launch a sustained attack against tumor cells.3 This is complicated, as the interactions between tumors and immune systemsometimes called the Cancer-Immunity Cycle (see Figure 1 in the slider above)4are complex and dynamic. The Cancer-Immunity Cycle manages the delicate balance between the immune systems ability to recognize non-self and the development of autoimmunity.

In some cases, the immune system may fail to recognize tumor cells as non-self and may develop a tolerance to them. Moreover, tumors have an armamentarium of methods for evading the immune system. Given this elaborate interplay between cancer and immunity, there is a wide range of potential cancer immunotherapy approaches:

The immune response to cancer involves a series of carefully regulated events that are optimally addressed as a group, rather than individually.4 The complexity of the immune response to cancer provides a strong rationale for combination therapies, for instance:

Increasingly, the development and deployment of immunotherapy relies on harnessing genomic data to identify the patients most likely to respond to immunotherapy and to customize immunotherapy for a given patient.6 Thus, molecular profiling technologies, such as next-generation sequencing, have become integral to drug development and patient selection. At the same time, researchers are focusing on identifying molecular alterations in tumors that may be linked to response.7 The molecular fingerprints of a tumor can be quite complex and heterogeneous, not only across tumors, but also within a single patient. Consequently, molecular tumor characterization requires both multidimensional data from laboratory and imaging tests and advanced software and computational methods for analyzing these data.8 This emergence of computational precision oncology is associated with both opportunities and challenges, from validation and translation to regulatory oversight and reimbursement.

The regulatory landscape is evolving to keep pace with technological advances in cell engineering and gene editing. Since 2013, the FDA has published four guidance documents on cellular and gene therapy products, as well as two guidance documents providing recommendations on regenerative medicine advanced therapies (RMATs). Specifically, their Expedited Programs for Regenerative Medicine Therapies for Serious Conditions, published in November 2017, provides guidance on the expedited development and review of regenerative medicine therapies for serious or life-threatening diseases and conditions. This document also provides information on the use of the accelerated approval pathway for therapies that have been granted the RMAT designation.9

In the EU, the European Medicines Agency (EMA) published a draft revision of its Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells in July 2018.10 This draft revision includes current thinking on the requirements for nonclinical and clinical studies, as well as specific sections on the scientific principles and clinical aspects of CAR-T products.

Precision medicines such as CAR-T therapies require manufacturers to transform a complex, individualized treatment into a commercial product. In conventional manufacturing, the entire manufacturing process occurs within the confines of the manufacturing facility. With cell therapies, however, the process begins with the collection of cells from the patient and ends with administration of the final product (see Figure 2 in the slider above). In between, the cells are handed off multiple times for the process of genetic modification, creating a complex supply chain that blends manufacturing and administration.11

Moreover, in contrast to traditional manufacturing where the starting materials are standardized or well-defined, the starting materials for cell therapies are derived from patients and, thus, highly variable.

As evidenced by the manufacturing challenges that plagued the launch of Kymriah (tisagenlecleucel), even pharmaceutical giants have struggled with meeting label specifications for commercial use.13 To help address its manufacturing hurdles, Novartis acquired CellforCure, a contract development manufacturing organization, and plans to transform by focusing on data and digital technologies.14,15 What this means for sponsors is that robust, scalable manufacturing must be incorporated into clinical developing planning at its earliest stages.

The high price tags associated with CAR-T therapies illustrate how expensive targeted therapies are in comparison to their traditional counterparts.16 Existing health insurance models have not been structured to reimburse for costly treatments that offer the potential for long-term benefit or even cure. The pricing model for CAR-T therapies may be especially challenging for private insurance companies, which have higher turnover and shorter coverage windows than national health insurance programs. For sponsors of precision medicine therapies, one way to address the challenge of reimbursement is to create innovative, value- or outcomes-based pricing models, rather than focusing on sales volume. The success of these new pricing models will rely on patient selection. To demonstrate value and optimizing outcomes, sponsors will need to develop profiles of patients who are most likely to respond and provide tools for identifying these patients.8

Of note, on August 7, 2019, the Centers for Medicare & Medicaid Services (CMS) finalized the decision to cover FDA-approved CAR-T therapies when provided in healthcare facilities enrolled in the FDA risk evaluation and mitigation strategies (REMS) for FDA-approved indications. Medicare will also cover FDA-approved CAR-T treatments for off-label uses that are recommended by CMS-approved compendia.17

Beyond the pharmaceutical companies that are working to develop personalized treatments, the precision medicine ecosystem has a number of other key stakeholdersregulators, payers, diagnostic companies, healthcare technology companies, healthcare providers and, of course, patients. Pharmaceutical companies need to engage with each of these stakeholders by providing education or developing partnerships that help demonstrate the need for high-quality data collection, the value of precision medicine, and the process for identifying the right patients.

Sponsors may also benefit from engaging with patient advocacy groups as these groups play a critical role in connecting patients and caregivers with scientific and healthcare experts to learn about how new immunotherapy breakthroughs are changing the standard of care.

Empowered patients pushing for the latest innovations are propelling precision medicine forward, but we still have a way to go before the full potential of precision medicine is realized. In its maturity, precision medicine will not only enable the personalization of treatments for individual patients, but also inform public health at a population level as insights from the genetic and molecular data collected are used to advance our understanding of disease. Robust data collection and analysis, along with standardization, are required for building this foundation of precision medicine, and multi-stakeholder buy-in is necessary for addressing issues around data integration and privacy.

While significant challenges remain, the opportunity to transform patient outcomes and population health with precision medicine is tantalizing. Increasingly, we are seeing advanced technologiessuch as artificial intelligence and machine learningbeing incorporated into the drug discovery and development process. This underscores the critical need for a multidisciplinary approach to precision medicine, from discovery at the bench all the way through to delivery at the bedside, to help ensure that more patients can access the right therapy at the right time, and the right price.

References

Read the original here:
Realizing The Full Potential Of Precision Medicine In Oncology - Contract Pharma